The GFPC 01-2018 registry included 23 HER2-mutated NSCLC patients who were treated by ICI and demonstrated 27.3% RR (six patients), with 2.2 months of PFS. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.